Company: RNAC
Filing Date: 2025-04-29
Form Type: 8-K
Source: 0001453687-25-000077
Chunk: 0

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-29
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 29, 2025, Cartesian Therapeutics, Inc. (the “ Company”) entered into a (i) consulting agreement (the “ Consulting Agreement”) and (ii) separation agreement and release (the “ Separation Agreement,” and together with the Consulting Agreement, the “ Agreements”), each with the Company’s Chief Technology Officer, Metin Kurtoglu.

Dr. Kurtoglu’s employment with the Company will end effective May 1, 2025, and pursuant to the Consulting Agreement, Dr. Kurtoglu will serve as a consultant to the Company for the term May 1, 2025 to April 30, 2026.

Pursuant to the Separation Agreement, Dr. Kurtoglu agreed to release the Releasees (as such term is defined in the Separation Agreement) from any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Dr. Kurtoglu may possess against any of the Releasees arising from any omissions, acts, facts, or damages that have occurred up until and including April 29, 2025, in consideration for receipt from the Company of the severance payments and benefits described in the employment agreement, dated March 28, 2024, by and between the Company and Dr. Kurtoglu, including payment of 12-months’ salary and eligibility for a pro-rated bonus, and the accelerated vesting of equity awards held by Dr. Kurtoglu granted on January 2, 2024 under any Company equity compensation plans.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  CARTESIAN THERAPEUTICS, INC.                                             
  By:                               /s/ Carsten Brunn, Ph. D.              
                                    Carsten Brunn, Ph. D.                  
                                    President and Chief Executive Officer